ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lilly’s Lechleiter to retire

by Lisa M. Jarvis
August 1, 2016 | APPEARED IN VOLUME 94, ISSUE 31

Lechleiter
[+]Enlarge
Credit: Eli Lilly & Co.
Credit: Eli Lilly & Co.
Ricks
[+]Enlarge
Credit: Eli Lilly & Co.
Credit: Eli Lilly & Co.

John C. Lechleiter will step down as president and CEO of Eli Lilly & Co. at the end of the year. Replacing him will be longtime Lilly executive David A. Ricks, who currently heads Lilly Bio-Medicines. Lechleiter, an organic chemist, joined Lilly in 1979 in its process research labs and moved up the ranks. He became CEO in 2008, when patent expirations on nearly all of Lilly’s key products loomed. Although Lechleiter helped the company mitigate some of the revenue loss by expanding in areas such as animal health, his tenure as CEO was marred by a string of drug pipeline setbacks.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment